加齢黄斑変性に対するラニビズマブの投与成績

Outcome of intravitreal ranibizumab for age-related macular degeneration

要約　目的：滲出性加齢黄斑変性に対するラニビズマブ硝子体内注射の結果の報告。対象と方法：34例36眼を対象とした。男性14例，女性20例で，平均年齢は75.4±9.5歳である。全症例に3回以上のラニビズマブ硝子体内注射を行った。16眼がラニビズマブを初回治療として受け，9眼が以前に光線力学的療法，8眼がベバシズマブ，3眼がその両治療を受けていた。平均135日の治療後経過を追った。結果：初回治療群では平均視力が0.26から0.31に，中心窩網膜厚は404μmから286μmになった。両治療群では平均視力が0.11から0.07に，中心窩網膜厚は431μmから353μmになり，改善が最も少なかった。結論：滲出性加齢黄斑変性に対するラニビズマブ硝子体内注射により，他の方法による治療歴があっても，視力が維持され，中心窩網膜厚が減少した。

Abstract.　Purpose：To report the outcome of intravitreal ranibizumab for exudative age-related macular degeneration. Cases：This retrospective study was made on 36 eyes of 34 patients. The series comprised 14 males and 20 females. The age averaged 75.4±9.5 years. All the cases received ranibizumab in 3 or more sessions. Ranibiumab injection was performed as the initial treatment in 16 eyes. Photodynamic therapy had been performed in 9 eyes. Intravitreal bevacizumab had been performed in 8 eyes. Three eyes had received both treatments. Cases were followed up for an average of 135 days. Results：In 16 treatment-naïve eyes,averaged visual acuity improved from 0.26 to 0.31. Foveal thickness decreased from 404μm to 286μm. In 3 eyes that had received both treatments,visual acuity changed from 0.11 to 0.07. Foveal thickness decreased from 431μm to 353μm. Conclusion：Intravitreal ranibizumab was followed by maintained visual acuity and decreased foveal thickness in age-related macular degeneration regardless of previous treatment.